News • 20-8-2015

Primary CV outcomes endpoint met by SGLT2 inhibitor in type 2 diabetes

Empagliflozin added to standard of care, showed superiority over standard of care in the long-term EMPA-REG OUTCOME trial in reducing CV events in a high-risk population with type 2 diabetes. Read more

Good adherence to antihypertensive treatment important to limit hypertension-associated HF risk

17-8-2015 • Corrao G et al. Hypertension 2015
A population-based case control study confirms low adherence to antihypertensive therapy. Improving adherence is important to lower risk of hospitalisation for heart failure. Read more

Cardio-metabolic benefits with standing or stepping instead of sitting

11-8-2015 • Healy GN et al., Eur Heart J. 2015
Replacing sitting time with standing or stepping beneficially impacts glucose and lipid metabolism, at volumes that seem feasible in workplace-setting interventions. Read more

Protection from stroke and ICH with edoxaban vs placebo, aspirin, or aspirin plus clopidogrel

4-8-2015 • Blann AD et al., Thromb Haemost. 2015
Network meta-analysis compared edoxaban with placebo, aspirin alone, or aspirin plus clopidogrel in AF in both clinical trial populations and unselected community populations. Read more

Most, but not all women have better prognosis than men after acute myocardial infarction

29-7-2015 • Redfors et al., J Am Heart Assoc. 2015
While women have better adjusted prognosis than men after AMI, this benefit was not seen in younger women and women with STEMI and women are less likely to be prescribed evidence-based treatment. Read more

Stroke detection and prevention in atrial fibrillation

23-7-2015 • Prof. Richard Hobbs - Br. J. Gen. Prac. 2015
Professor Richard Hobbs, Chairman of EPCCS Scientific Organising Committee, wrote an editorial in the July issue of Br J Gen Prac, in which three articles on stroke and its better prevention are published. Read more

In T2DM patients with CAD, achieving multiple risk factor goals yields more CV benefit

19-8-2015 • Bittner et al, JACC 2015
Patients with T2DM and CHD in whom risk factors were managed with protocol-guided therapy, showed lower risks of CV events and mortality when more risk factors were in control. Read more
News • 13-8-2015

Pre-hospital and early hospital management of acute heart failure

Consensus paper on optimal management of acute heart failure, benefitting from experience of various clinical settings involved, has been produced by three international societies.   Read more
News • 6-8-2015

Online Learning - EPCCS SPAF Consensus Document

PeerVoice Education developed a learning activity about the EPCCS SPAF Consensus Document: "Expert Insights on EPCCS Recommendations for Stroke Prevention in Atrial Fibrillation: What General Practitioners Need to Know". Read more

Patients with type 2 diabetes should not skip breakfast

30-7-2015 • Jakubowicz et al., Diabetes Care 2015
Eating breakfast is important for patients with type 2 diabetes, because it improves glucose homeostasis throughout the day, and postprandial hyperglycaemia can be prevented. Read more
News • 27-7-2015

Another PCSK9-inbitor on its way to European approval for hypercholesterolaemia

The FDA has approved alirocumab injections, and the European EMA has recommended approval of this PCKS9-inhibitor as an adjunct to diet and other lipid-lowering drugs. Read more
News • 22-7-2015

First PCSK9-inhibitor now approved by EMA for treatment of hypercholesterolaemia

Evolocumab is the first PCSK9 inhibitor to be approved worldwide, which means a milestone for patients with uncontrolled cholesterol who require additional intensive LDL-C reduction. Read more

Upcoming meetings

Meeting reports & resources

EPCCS Guidance Documents Evidence- and meeting-based guidance for primary care
EPCCS 2015 Report of 8th Annual EPCCS meeting held in Prague.
EPCCS 2014 Report of 7th Annual EPCCS meeting held in Brussels.
EPCCS 2013 Report of 6th Annual EPCCS meeting held in London
All meeting reports...